ONCOLYS BIOPHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 717 JPY | +4.37% |
|
+0.28% | +26.46% |
More news
More press releases
| 1 day | +4.37% | ||
| 1 week | +0.28% | ||
| Current month | -9.13% | ||
| 1 month | +15.46% | ||
| 3 months | +28.49% | ||
| 6 months | +19.90% | ||
| Current year | +26.46% |
1 week
625.00
730.00
1 month
599.00798.00
Current year
510.00798.00
1 year
504.00798.00
3 years
466.001 938.00
5 years
466.003 820.00
10 years
401.004 410.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yasuo Urata
FOU | Founder | 68 | 04-03-17 |
Kohei Hata
DFI | Director of Finance/CFO | - | 18-12-31 |
| Director/Board Member | 58 | 07-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yasuo Urata
FOU | Founder | 68 | 04-03-17 |
Naoko Iino
BRD | Director/Board Member | 63 | 23-02-28 |
| Director/Board Member | 58 | 07-11-30 |
Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +26.46% | 90.07M | |
| -2.68% | 85.68B | |
| +4.08% | 41.4B | |
| -25.35% | 28.22B | |
| +54.31% | 24.64B | |
| -4.52% | 16.98B | |
| -42.09% | 13.29B | |
| -17.77% | 11.66B | |
| -12.10% | 11.65B | |
| +0.75% | 8.18B |
- Stock Market
- Equities
- 4588 Stock
